<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160480</url>
  </required_header>
  <id_info>
    <org_study_id>EXPLLN21-01</org_study_id>
    <nct_id>NCT05160480</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG</brief_title>
  <official_title>A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lantheus Medical Imaging</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test new ways to improve the usefulness of the&#xD;
      world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner&#xD;
      (EXPLORER) by collecting data from PET scans using one of three different imaging agents:&#xD;
      18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used&#xD;
      for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE),&#xD;
      or breast cancer (18F-FES).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measure radiotracer avidity</measure>
    <time_frame>One study imaging visit lasting up to 10 hours</time_frame>
    <description>measure radiotracer avidity, i.e. standardized uptake value measurements (SUV max and mean) of tumor and normal tissue as a function of time with 18F-PSMA, 18F-FES, 68Ga DOTATATE in a total-body PET scanner among men with suspected prostate cancer metastasis, patients suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors, and patients with recurrent or metastatic breast cancer.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Total-body PET scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Total-body PET imaging</intervention_name>
    <description>Total-body PET imaging at different timepoints</description>
    <arm_group_label>Total-body PET scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        18F-PSMA (n=3)&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Men &gt;18 yo with suspected prostate cancer metastasis who are candidates for initial&#xD;
             definitive therapy or with suspected recurrence based on elevated serum PSA level&#xD;
&#xD;
          -  Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan)&#xD;
             suspicious for metastatic disease, obtained not earlier than 4 months from the&#xD;
             research scan date.&#xD;
&#xD;
             68Ga DOTATATE (n=3)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Persons &gt; 18 yo suspicious for or diagnosed with somatostatin receptor positive&#xD;
             neuroendocrine tumors (NETs)&#xD;
&#xD;
          -  Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months&#xD;
             from the research scan date.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent administration of long-acting somatostatin analogs&#xD;
&#xD;
             18F-FES (n=3):&#xD;
&#xD;
          -  Persons &gt; 18 yo with recurrent or metastatic breast cancer&#xD;
&#xD;
          -  Prior imaging study (CT, and/or US, and/or MRI, and/or bone scan and/or FDG PET/CT)&#xD;
             suspicious for tumor, obtained not earlier than 4 months from the research scan date.&#xD;
&#xD;
          -  Biopsy proven ER-positive breast cancer (any location) in the past 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ History of ER modulators and ER down-regulators such as tamoxifen and fulvestrant in the&#xD;
        past 8 and 28 weeks, respectively&#xD;
&#xD;
        Exclusion Criteria for all participants:&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Pregnant/lactating persons&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Unable to lie supine for up to 90 minutes at different timepoints in the PET scanner&#xD;
&#xD;
          -  Uncontrolled claustrophobia&#xD;
&#xD;
          -  Any significant medical condition that in the opinion of the investigator would&#xD;
             prevent the subject from participating and/or adhering to study related procedures or&#xD;
             interfere with subject safety&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC Davis EXPLORER Molecular Imaging Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

